We evaluated the response of patients with PAAD in different risk groups to ICIs by IPS scores and found that the IPS (PD-1/PD-L1/PD-L2(-) and CTLA-4(-)) scores of patients in the high-risk group were significantly higher in the lower-risk group(P< 0.01, Figure 8E), rather than IPS-PD1/PDL1/PDL2 blocker score, IPS-CTLA4 blocker score, and IPS-CTLA4 and PD1/PDL1/PDL2 blocker score (Supplementary Figure 2). This evidence concerns the gene CD274 and pancreatic adenocarcinoma.